The new year is coming, please remember to update your insurance with us. We require a copy of your insurance card every year, even if there are no changes.

Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy

Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an On-going Observational IL-2 Clinical Trial: PROCLAIM

“manuscript in publication”

Call • Fax • Convenient Locations

#caringforthegoodlife

The new year is coming, please remember to update your insurance with us. We require a copy of your insurance card every year, even if there are no changes.

Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy

More articles »